Treatments for metastatic uveal melanoma utilize various liver-directed strategies, yet optimal integration with systemic therapy is unclear. Here we examine recent evidence indicating that combining percutaneous hepatic perfusion with immune-checkpoint inhibitors might improve patient outcomes, compare it with data from other trials and highlight key questions around patient selection, sequencing and mechanisms that will shape future strategies.
- Shaheer A. Khan
- Richard D. Carvajal
